Endonovo Therapeutics

What Endonovo Therapeutics does

Endonovo Therapeutics is a publicly traded (OTCQB: ENDV) biotechnology company headquartered in Woodland Hills, California, with 11-50 employees. The company develops non-invasive, wearable medical devices that deliver its proprietary Electroceutical Therapy using Pulsed Electromagnetic Fields (PEMF) at 27.12 MHz to accelerate endogenous nitric oxide synthesis, triggering anti-inflammatory and growth factor cascades for healing. Its commercial-stage product, SofPulse, is FDA-cleared for palliative treatment of pain and post-surgical edema, CE-marked for wound healing promotion, and has CMS National Coverage for chronic wound treatment. The company distributes these prescription-only devices through healthcare facilities — hospitals, outpatient surgery centers, wound care centers, and medical spas — via direct enterprise sales rather than direct-to-patient channels.

The company's revenue model is primarily hardware sales of single-patient-use SofPulse consumable units, supplemented by clinical pipeline development targeting cardiovascular and central nervous system indications (ischemic heart disease, TBI, concussions, multiple sclerosis) through research partnerships with academic medical centers including Cleveland Clinic Florida, Columbia University, UCSF, and the University of New Mexico. Endonovo monetizes through unit pricing on devices and pursues one-time licensing opportunities tied to its clinical pipeline. The company holds 12 issued US patents and 2 EU patents covering electromagnetic treatment apparatus and methods, with trademarks including Electroceutical, SofPulse, ROMA, and TORINO. Leadership includes Chairman & CEO Alan Collier (corporate finance background), President & CCO Ira Weisberg (pharma commercialization experience including >$100M in licensing deals), and Chief Scientist Dr. Donnie Rudd (NASA-recognized inventor of TVEMF technology).

The company evolved from Hanover Portfolio Acquisitions, which acquired WeHealAnimals, Inc. in November 2013, and subsequently acquired Rio Grande Neurosciences in July 2016. Endonovo has raised approximately $15.5M across three funding rounds between 2014 and 2016. No current revenue is publicly disclosed; the company's clinical-stage pipeline assets and regulatory clearances represent the primary sources of strategic value, with commercial revenue from SofPulse hardware sales remaining undisclosed.

Name

Endonovo Therapeutics

Legal name

Endonovo Therapeutics, Inc.

Website

https://endonovo.com

Company type

Public

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Endonovo Therapeutics (OTCQB: ENDV) is a Woodland Hills, CA-based medical device company developing FDA-cleared, non-invasive SofPulse wearable devices using Pulsed Electromagnetic Field therapy to treat post-surgical pain, edema, and chronic wounds. It sells prescription devices to hospitals, surgery centers, and wound care facilities.

Ownership category

akta.pro rank

Product category

Therapeutic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips) (HLAHALAD)

akta.pro secondary industry

Pain Medicine (Interventional/Neuropathic Pain) (HLAKAIAM)

Keywords

• Pulsed electromagnetic therapy
• Post-surgical pain management
• Medical device
• Wound healing devices
• Electroceutical therapy

Headquarters

HQ city

Woodland Hills

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Medical Device Sales: Sale of SofPulse and SofPulse Duo prescription medical devices. Products are sold in single-patient-use quantities with product numbers 1IVSP7.5 (SofPulse 7.5 Single Patient Use) and 1IVSPDUOWHT (SofPulse Duo Single Patient Use). Distribution is prescription-only through medical facilities.
2. Clinical Pipeline Development: Company is developing clinical-stage Electroceutical Therapies targeting cardiovascular diseases and central nervous system disorders including ischemic heart disease, acute concussions, post-concussion syndrome, traumatic brain injury (TBI) and multiple sclerosis through its EFFECT Trial and other clinical programs.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Endonovo Therapeutics develops and sells non-invasive, wearable medical devices that deliver its proprietary Electroceutical Therapy using pulsed electromagnetic fields (PEMF) at 27.12 MHz. Its core commercial product SofPulse is FDA-cleared for palliative treatment of pain and post-surgical edema, CE-marked for wound healing, and CMS-covered for chronic wounds. The company also maintains a clinical pipeline of Electroceutical Therapies targeting ischemic heart disease, TBI, concussions, and multiple sclerosis.

Product overview

Endonovo Therapeutics offers a portfolio of non-invasive medical devices centered on its proprietary Electroceutical® Therapy platform. The core commercial product is SofPulse® Electroceutical® Therapy, which delivers pulsed electromagnetic fields at 27.12 MHz via wearable devices to treat pain, post-surgical edema, and promote wound healing. The Electroceutical® Therapy platform is FDA-cleared and CE-marked, with CMS National Coverage for chronic wounds. The company also markets Roma® as another PEMF medical device brand. The technology works by delivering microcurrents that stimulate the body's endogenous nitric oxide production to trigger anti-inflammatory and growth factor cascades necessary for natural healing.

Differentiator

Problem solved

Functional benefit

Brands

• SofPulse®: FDA-Cleared and CE Marked electroceutical therapy device for palliative treatment of pain and post-surgical edema, CMS National Coverage for chronic wounds.
• Electroceuticals®
• ROMA
• TORINO
• WOUNDPULSE

Products and services

• SofPulse Electroceutical Therapy A non-invasive, wearable medical device that delivers targeted microcurrents via pulsed electromagnetic fields (PEMF) at 27.12 MHz to reduce post-surgical edema and accelerate natural recovery. FDA-cleared for palliative treatment of pain and post-surgical edema, CE-marked for wound healing promotion, and covered by CMS National Coverage for chronic wounds. Sold in single-patient-use quantities (1IVSP7.5 and 1IVSPDUOWHT) as a prescription device through licensed medical facilities.
• Electroceutical Therapy Platform Endonovo's proprietary therapeutic platform using induction via pulsed radio-frequency (PRF) waves at 27.12 MHz that accelerates endogenous nitric oxide synthesis (cNOS/eNOS) to trigger anti-inflammatory and growth factor cascades. Delivered through non-invasive, wearable medical devices and currently in clinical development for cardiovascular diseases, central nervous system disorders, ischemic heart disease, TBI, concussions, and multiple sclerosis.
• Roma PEMF Medical Device A branded pulsed electromagnetic field medical device within Endonovo's product portfolio. The Roma trademark is registered with the US Patent and Trademark Office and represents a PEMF device sub-brand.

Quantifiable outcome

• 57% decrease in mean pain scores at one hour post-procedure (p<0.01)
• +6 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Partnerships

One partnership is on record.

• WeHealAnimals, Inc.coreStrategic or Co-development Partner · 20 November 2013Hanover Portfolio Acquisitions acquired WeHealAnimals, Inc., a biotechnology company with intellectual property for square-waveform Time-Varying Electromagnetic Frequencies (TVEMF) to promote stem cell mobilization and tissue regeneration. Dr. Donnie Rudd, founder of WeHealAnimals and NASA-recognized inventor, joined as Chief Scientist and Director of Intellectual Property. WHA's technology was developed at NASA for space applications and expanded to veterinary and human medical applications.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Nevro Corp: Nevro develops implantable neuromodulation devices for chronic pain (HF10 therapy). Comparable in clinical application (neurological pain) but operates invasively in a different delivery modality, making it a complementary / adjacent competitor for pain indications.
• DJO (Enovis): DJO/Enovis is a large orthopedic and rehabilitation device company offering pain management and electrotherapy products (e.g., Chattanooga electrotherapy line). It competes broadly in the same clinical use cases (post-op pain, edema) but as part of a much larger portfolio rather than as a PEMF pure-play.
• Abbott (St. Jude Medical): Abbott's neuromodulation franchise (formerly St. Jude Medical) targets chronic pain and movement disorders. Relevant as a broad incumbent potentially positioned to license or acquire Endonovo's CNS pipeline assets given comparable therapeutic focus.
• Medtronic: Medtronic operates broadly in neuromodulation and pain management devices (spinal cord stimulators, targeted drug delivery) — relevant as an incumbent that could partner with or acquire Endonovo's CNS pipeline (TBI, MS) if pivotal data emerge.

Direct peers

• BTL Group: BTL Group produces non-invasive electromagnetic and shockwave medical devices for pain management, physiotherapy, and aesthetic medicine. Its PEMF-based platforms compete directly with Endonovo's Electroceutical Therapy in clinics, medical spas, and rehabilitation centers globally.
• Orthofix Medical: Orthofix manufactures and sells Pulsed Electromagnetic Field (PEMF) bone growth stimulation devices (e.g., CervicalStim, SpinalStim, PhysioStim) for orthopedic indications — directly competing in PEMF hardware sold to hospitals and physicians and overlapping in post-surgical recovery applications.
• Regenesis Biomedical: Regenesis Biomedical markets Provant Therapy, a pulsed radio frequency energy wound healing device cleared by FDA. It competes directly with Endonovo's SofPulse in the same PEMF-based wound healing category with overlapping CMS reimbursement positioning.
• BioElectronics Corporation: BioElectronics develops wearable PEMF devices (ActiPatch, RecoveryRx) for pain management, post-surgical recovery, and wound healing. Overlapping product positioning, target customers (hospitals, consumers), and electromagnetic therapy technology make it a direct comparison.
• Ivivi Health Sciences: Ivivi Health Sciences develops PEMF devices (formerly known as Ivivi Technologies) targeting wound healing, pain, and orthopedic indications. It is one of the closest direct competitors to Endonovo's SofPulse platform in regulatory positioning and clinical indications.

Emerging players

• Stimwave Technologies: Stimwave (now part of Acom Healthcare) develops miniaturized wireless neurostimulators for chronic pain — an emerging competitor in pain management that intersects with Endonovo's neuro-pain pipeline positioning, though operating in a different modality (implantable).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• Facebookfacebook.com/endonovo
• LinkedInlinkedin.com/company/2881561
• Xx.com/endonovo

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Endonovo Therapeutics